Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 13/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.38 |
| ▸ | UGT8 | Q16880 | 3/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23679949 | 0.92 | CYP11B2 (0.46) | CYP11B2CYP11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18791006 | 0.84 | CYP11B2 (0.42) | CYP11B2CYP11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22236812 | 0.78 | CYP11B2 (0.51) | CYP11B2CYP11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18791093 | 0.77 | CYP11B2 (0.66) | CYP11B2CYP11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18790700 | 0.76 | CYP11B2 (0.56) | CYP11B2CYP11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18790969 | 0.76 | CYP11B2 (0.52) | CYP11B2CYP11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18790702 | 0.76 | CYP11B2 (0.52) | CYP11B2CYP11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23679948 | 0.75 | CYP11B2 (0.53) | CYP11B2CYP11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18791021 | 0.74 | CYP11B2 (0.69) | CYP11B2CYP11B1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL20340176 | 0.71 | CYP11B2 (0.77) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3381904-B1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2020-07-21 | — | — | US | disclosed |
| WO-2017069226-A1 | NOVEL NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND | 田辺三菱製薬株式会社 | 2017-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10717731-B2 | Nitrogen-containing aromatic heterocyclic compound | REN, NR3C2, NR5A1 | CYP11B2 8/4885CYP11B1 6/4885KDM4E 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.